Return to content in this issue
Mepolizumab treatment for severe eosinophilic asthma: a 5-years real-life experience
Loli-Ausejo D1,2*, Perdomo G3*, Mascaró B1,2, Martínez-Olondris P2,4, Sánchez-Fernández MC1, Mullol J2,5,6, Valero A1,2,6, Arismendi E2,4,6#, Bobolea I1,2,6#
1Department of Allergy, Hospital Clínic Barcelona, Barcelona, Spain
2Clinical and Experimental Respiratory Immunoallergy (IRCE), August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalonia, Spain
3Department of Allergy, Hospital Santa Creu i Sant Pau, Barcelona, Spain
4Department of Pneumology, Hospital Clínic Barcelona, Barcelona, Spain
5Rhinology Unit & Smell Clinic, ENT Department, Hospital Clinic Barcelona, Universitat de Barcelona, Barcelona, Spain
6CIBER of Respiratory Diseases (CIBERES), Health Institute Carlos III
* These authors have contributed equally to this work.
# These authors have contributed equally to this work and share senior authorship.
J Investig Allergol Clin Immunol 2023; Vol. 33(6)
doi: 10.18176/jiaci.0898
Key words: Asthma,Severe eosinophilic asthma, Mepolizumab, Monoclonal antibodies, Treatment
Title | Type | Size | |
---|---|---|---|
![]() |
doi10.18176_jiaci.0898_supplemental-materials-tables.pdf | 295.51 Kb |